HHHideyuki Harada

Hideyuki Harada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hideyuki Harada has a total of 242 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Particle therapy for T3N0M0 non-small cell lung cancer: a Japanese nationwide prospective registry study

    by Masaki Nakamura, Nobuteru Kubo, Kazushi Maruo, Masao Murakami, Hiromitsu Iwata, Sunao Tokumaru, Takahiro Waki, Genki Adachi, Kimihiro Shimizu, Yasushi Goto, et al.

  • Open Access

    A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART)

    by Kota Kawabata, Fumiharu Ohka, Ryuta Saito, Tsuyoshi Onoe, Hideyuki Harada, Takashi Sasayama, Hideaki Yokoo, Yoshiki Arakawa, Junki Mizusawa, Noriko Mitome, et al.

    Primary central nervous system lymphoma (PCNSL) is an aggressive malignancy. Patients refractory to high-dose methotrexate–based induction therapy have an extremely poor prognosis. Although whole-brain radiotherapy (WBRT) is the standard salvage treatment and provides potent tumor control, early functional deterioration and late neurocognitive toxicity remain major concerns. A phase I/II trial on relapsed or refractory PCNSL demonstrated favorable efficacy and tolerability of tirabrutinib, a second-generation selective Bruton’s tyrosine kinase inhibitor. Tirabrutinib’s oral administration has enabled outpatient management. However, its clinical value for induction-refractory PCNSL remains uncertain. We designed a multicenter, randomized phase II/III trial (JCOG2314) to assess the non-inferiority of tirabrutinib to WBRT in overall survival and its potential to reduce functional deterioration and cognitive impairment. A total of 94 patients from 49 institutions will be enrolled over 4 years. The trial has been registered in the Japan Registry of Clinical Trials (study number: jRCT1031250645).

  • Open Access

    Long-term outcomes of concurrent chemo-proton therapy for unresectable stage III non-small cell lung cancer: a Japanese national registry study

    by Hiromitsu Iwata, Masao Murakami, Kazushi Maruo, Masaki Nakamura, Takahiro Waki, Masatoshi Nakamura, Hiroshi Taguchi, Kazuya Inoue, Masayuki Araya, Hitoshi Tatebe, et al.


  • Comparison of treatment outcomes between stereotactic body radiotherapy/proton beam therapy and sublobar resection for vulnerable elderly patients with stage IA non-small cell lung cancer

    by Momoko Asami, Shinya Katsumata, Kazuaki Yasui, Daisuke Yamaguchi, Tatsuya Masuda, Hideaki Kojima, Hayato Konno, Mitsuhiro Isaka, Hideyuki Harada, Yasuhisa Ohde

    Objective: The aim of this study was to compare survival and the incidence of complications between stereotactic body radiotherapy/proton beam therapy (SBRT/PBT) and sublobar resection for vulnerable elderly patients with clinical stage IA non-small cell lung cancer (NSCLC). Methods: We included patients aged ≥75 years who underwent sublobar resection without mediastinal lymph node dissection or SBRT/PBT for solid predominant clinical stage IA non-small cell lung cancer measuring ≤3 cm in total size. Propensity score matching was used to reduce the selection bias. Complication and survival rates were compared between groups. Results: Of the 119 included patients, 86 received stereotactic body radiotherapy (62 received X-ray radiotherapy and 24 received proton beam therapy), while 33 received sublobar resection (11 received segmentectomy and 22 received wedge resection). The SBRT/PBT group included significantly older patients (median: 82 vs. 79 years) and larger tumors (median: 18 vs. 16 mm) than did the surgery group. After propensity score matching, 24 patients were analysed in each group. The incidence of ≥Grade 2 complications was not significantly different between the two groups (12.5% vs. 29.1%; OR = 0.35, 95% CI: 0.08–1.55; P = 0.286). Moreover, there were no significant differences in overall and recurrence-free survival rates (OS: HR = 0.68; 95% CI: 0.31–1.50; P= 0.343; RFS: HR = 0.69; 95% CI: 0.33–1.46; P = 0.336, respectively) and the cumulative incidence of recurrence (sHR = 0.87; 95% CI: 0.31–2.40; P = 0.781). Conclusions: For vulnerable elderly patients with NSCLC, SBRT/PBT may be comparable with sublobar resection in terms of patient survival and safety. Prospective randomized controlled trials are required to confirm these findings.

  • Open Access

    Inter-institutional variability in CT-to-mass-density conversion tables for helical tomotherapy: a national survey in Japan

    by Shogo Tsunemine, Shuichi Ozawa, Ryosei Nakada, Yasuo Shiota, Satoshi Kito, Hidetoshi Shimizu, Takashi Hashido, Takehiro Shiinoki, Yuto Kitagawa, Hiroshi Fukuma, et al.

    This study evaluates current practices and challenges associated with computed tomography number-to-mass density (CT–MD) conversion tables in helical tomotherapy across Japan and explores directions for standardization and quality improvement amid the increasing adoption of adaptive radiotherapy (ART). A nationwide web-based survey was conducted across 34 institutions utilizing the Radixact system. Data were collected on CT acquisition protocols, calibration phantoms, density plugs, reconstruction algorithms, table registration timing and quality assurance (QA) frequency. Registered CT–MD tables were categorized by CT modality: Simulation CT (SimCT), ClearRT and CTrue. ClearRT tables were analyzed by phantom setup (full vs half), and CTrue tables by reconstruction method [filtered back projection (FPB) vs iterative reconstruction (IR)]. Inter-institutional variations in CT numbers and the number of data points were assessed. SimCT tables exhibited the widest variation in the number of data points (median = 10) and high-density CT numbers. ClearRT tables (median = 8) showed variations of up to 300 Hounsfield units (HU) in cortical bone; the half-phantom setup reduced inter-institutional variability. CTrue tables (median = 8) demonstrated high consistency, with negligible differences between IR and FPB. All plug CT numbers of CTrue remained within the tolerance defined by the American Association of Physicists in Medicine Task Group 148. However, CT numbers for air plugs varied by ~±30 HU, indicating inconsistent handling of air reference values. Additionally, 43% of institutions did not perform routine QA. Standardizing phantom geometry, air CT number handling and QA protocols—particularly using half-phantom calibration—may improve CT–MD table consistency and dose accuracy in ART.


  • Open Access

    Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study

    by Yuichiro Nishibori, Hirotsugu Kenmotsu, Kenju Ando, Ayumi Tonsho, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Kosei Doshita, Noboru Morikawa, Keita Miura, et al.

  • Open Access

    Multi-institutional prospective observational study of radiotherapy for metastatic bone tumor

    by Hideyuki Harada, Naoto Shikama, Akifumi Notsu, Hiroki Shirato, Kazunari Yamada, Haruka Uezono, Yutaro Koide, Hikaru Kubota, Takuya Yamazaki, Kei Ito, et al.

    Purpose of this study is to evaluate patient characteristics, treatments and outcomes in bone metastasis radiotherapy practice. Patients for whom radiotherapy for bone metastasis was planned at 26 institutions in Japan between December 2020 and March 2021 were consecutively registered in this prospective, observational study. Study measures included patient characteristics, pain relief, skeletal-related events (SREs), overall survival and incidence of radiation-related adverse events. Pain was evaluated using a numerical rating scale (NRS) from 0 to 10. Irradiated dose was analyzed by the biologically effective dose (BED) assuming α/β = 10. Overall, 232 patients were registered; 224 patients and 302 lesions were fully analyzed. Eastern Cooperative Oncology Group Performance Status was 0/1/2/3/4 in 23%/38%/22%/13%/4%; 59% of patients had spinal metastases and 84% had painful lesions (NRS ≥ 2). BED was <20 Gy (in 27%), 20–30 Gy (24%), 30–40 Gy (36%) and ≥ 40 Gy (13%); 9% of patients were treated by stereotactic body radiotherapy. Grade 3 adverse events occurred in 4% and no grade 4–5 toxicity was reported. Pain relief was achieved in 52% at 2 months. BED is not related to pain relief. The cumulative incidence of SREs was 6.5% (95% confidence interval (CI) 3.1–9.9) at 6 months; no factors were significantly associated with SREs. With spinal lesions, 18% of patients were not ambulatory at baseline and 50% of evaluable patients in this group could walk at 2 months. The 6-month overall survival rate was 70.2% (95% CI 64.2–76.9%). In conclusion, we report real-world details of radiotherapy in bone metastasis.


  • Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry

    by Hideyuki Harada, Hiroaki Suefuji, Keita Mori, Hitoshi Ishikawa, Masaki Nakamura, Sunao Tokumaru, Masao Murakami, Takashi Ogino, Hiromitsu Iwata, Hitoshi Tatebe, et al.


  • Open Access

    Correction: Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases

    by Masanori Hirata, Kazuaki Yasui, Naofumi Oota, Hirofumi Ogawa, Tsuyoshi Onoe, Sayo Maki, Yusuke Ito, Kenji Hayashi, Hirofumi Asakura, Shigeyuki Murayama, et al.


  • Open Access

    Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases

    by Masanori Hirata, Kazuaki Yasui, Naofumi Oota, Hirofumi Ogawa, Tsuyoshi Onoe, Sayo Maki, Yusuke Ito, Kenji Hayashi, Hirofumi Asakura, Shigeyuki Murayama, et al.

    Background: Linac-based fractionated stereotactic radiotherapy (fSRT) and stereotactic radiosurgery (SRS) are increasingly being used to manage patients with multiple metastases. This retrospective cohort study aimed to compare the outcomes after linac-based fSRT and SRS between three patient groups classified based on the number of brain metastases (BMs): 1 BM, 2–4 BM, 5–10 BM. Methods: The data of consecutive patients with 1–10 BMs treated with fSRT or SRS between July 2016 and June 2018 at a single institution were collected. Patients with previous whole-brain radiotherapy (WBRT), concurrent use of WBRT, or surgical resection were excluded from the analysis. A total of 176 patients were classified into three groups according to the number of BMs: 78, 67, and 31 patients in 1 BM, 2–4 BM, and 5–10 BM, respectively. The Kaplan–Meier method was used to estimate overall survival (OS) curves, and the cumulative incidence with competing risks was used to estimate local control (LC), distant intracranial failure (DIF), and radiation necrosis (RN). Results: Median OS was 19.8 months (95% confidence interval [CI] 10.2–27.5), 7.3 months (4.9–11.1), and 5.1 months (4.0–9.0) in 1 BM, 2–4 BM, and 5–10 BM, respectively. Compared to 2–4 BM, 1 BM had significantly better OS (hazard ratio [HR] 0.59, 95% CI 0.40–0.87; p = 0.0075); however, 5–10 BM had comparable OS (HR 1.36, 95% CI 0.85–2.19; p = 0.199). There was no significant difference in LC, DIF, and RN between tumor number groups, but DIF was lower in 1 BM. RN of grade 2 or higher occurred in 21 patients (13.5%); grade 4 and 5 RN were not observed. Conclusions: The linac-based fSRT and SRS for patients with 5–10 BMs is comparable to that for patients with 2–4 BMs in OS, LC, DIF, and RN. It seems reasonable to use linac-based fSRT and SRS in patients with 5–10 BMs.